SCYNEXIS (SCYX) Competitors $0.98 -0.01 (-0.59%) Closing price 04:00 PM EasternExtended Trading$0.99 +0.01 (+0.80%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCYX vs. LRMR, NBTX, PBYI, CYBN, ACRS, EPRX, NLTX, ADCT, FATE, and NKTXShould you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Larimar Therapeutics (LRMR), Nanobiotix (NBTX), Puma Biotechnology (PBYI), Cybin (CYBN), Aclaris Therapeutics (ACRS), Eupraxia Pharmaceuticals (EPRX), Neoleukin Therapeutics (NLTX), ADC Therapeutics (ADCT), Fate Therapeutics (FATE), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry. SCYNEXIS vs. Larimar Therapeutics Nanobiotix Puma Biotechnology Cybin Aclaris Therapeutics Eupraxia Pharmaceuticals Neoleukin Therapeutics ADC Therapeutics Fate Therapeutics Nkarta Larimar Therapeutics (NASDAQ:LRMR) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking. Is LRMR or SCYX more profitable? Larimar Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -425.41%. Larimar Therapeutics' return on equity of -35.87% beat SCYNEXIS's return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -35.87% -32.37% SCYNEXIS -425.41%-66.21%-38.84% Which has more volatility and risk, LRMR or SCYX? Larimar Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Do insiders & institutionals have more ownership in LRMR or SCYX? 91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 2.9% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend LRMR or SCYX? Larimar Therapeutics presently has a consensus price target of $19.63, indicating a potential upside of 628.20%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Larimar Therapeutics is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, LRMR or SCYX? SCYNEXIS has higher revenue and earnings than Larimar Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$36.95M-$1.30-2.07SCYNEXIS$3.75M10.35$67.04M-$0.44-2.26 Does the MarketBeat Community believe in LRMR or SCYX? SCYNEXIS received 459 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. However, 71.88% of users gave Larimar Therapeutics an outperform vote while only 69.66% of users gave SCYNEXIS an outperform vote. CompanyUnderperformOutperformLarimar TherapeuticsOutperform Votes4671.88% Underperform Votes1828.13% SCYNEXISOutperform Votes50569.66% Underperform Votes22030.34% Does the media refer more to LRMR or SCYX? In the previous week, Larimar Therapeutics had 6 more articles in the media than SCYNEXIS. MarketBeat recorded 7 mentions for Larimar Therapeutics and 1 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.93 beat Larimar Therapeutics' score of 0.67 indicating that SCYNEXIS is being referred to more favorably in the news media. Company Overall Sentiment Larimar Therapeutics Positive SCYNEXIS Positive SummaryLarimar Therapeutics beats SCYNEXIS on 11 of the 18 factors compared between the two stocks. Get SCYNEXIS News Delivered to You Automatically Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCYX vs. The Competition Export to ExcelMetricSCYNEXISPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.79M$6.75B$5.51B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-1.347.3222.5518.49Price / Sales10.35239.19394.97102.66Price / Cash0.5865.8538.1834.62Price / Book0.516.436.694.25Net Income$67.04M$143.21M$3.22B$248.31M7 Day Performance-6.57%1.24%1.11%1.12%1 Month Performance5.58%6.09%3.59%3.68%1 Year Performance-42.15%-3.34%15.65%5.19% SCYNEXIS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCYXSCYNEXIS1.0119 of 5 stars$0.98-0.6%N/A-41.5%$38.28M$3.75M-1.3360Upcoming EarningsAnalyst ForecastLRMRLarimar Therapeutics1.7324 of 5 stars$2.35+0.9%$19.63+735.1%-61.5%$150.47MN/A-2.0430Earnings ReportUpcoming EarningsOptions VolumeNews CoverageGap UpNBTXNanobiotix1.9532 of 5 stars$3.19+1.3%$8.00+150.8%-43.0%$150.35M$-11,609,000.000.00100Gap DownPBYIPuma Biotechnology3.8149 of 5 stars$2.98-0.7%$7.00+134.9%-37.3%$147.84M$230.47M6.21200Upcoming EarningsAnalyst RevisionNews CoverageCYBNCybin1.5936 of 5 stars$6.87-1.7%$86.00+1,151.8%+1,820.0%$147.55MN/A-1.5750ACRSAclaris Therapeutics3.1428 of 5 stars$1.36+1.5%$11.67+757.8%+14.0%$147.26M$18.72M-2.62100Upcoming EarningsShort Interest ↓News CoveragePositive NewsEPRXEupraxia Pharmaceuticals2.9665 of 5 stars$4.04+6.0%$10.50+159.9%+49.6%$144.83MN/A-5.6129Positive NewsNLTXNeoleukin TherapeuticsN/A$15.41+0.3%N/A-61.0%$144.82MN/A-4.9590Gap DownHigh Trading VolumeADCTADC Therapeutics1.4153 of 5 stars$1.46+9.8%$7.75+430.8%-67.7%$144.81M$70.84M-0.61310Upcoming EarningsGap UpFATEFate Therapeutics3.7548 of 5 stars$1.25-2.3%$5.43+334.3%-67.6%$143.26M$13.63M-0.76550Upcoming EarningsNKTXNkarta2.828 of 5 stars$2.01-4.7%$14.86+639.2%-68.3%$142.63MN/A-1.07140Upcoming EarningsPositive News Related Companies and Tools Related Companies LRMR Alternatives NBTX Alternatives PBYI Alternatives CYBN Alternatives ACRS Alternatives EPRX Alternatives NLTX Alternatives ADCT Alternatives FATE Alternatives NKTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCYX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SCYX Stock Free SCYX Stock Alerts